EA026902B1 - Способ лечения системной красной волчанки эпратузумабом - Google Patents

Способ лечения системной красной волчанки эпратузумабом Download PDF

Info

Publication number
EA026902B1
EA026902B1 EA201270433A EA201270433A EA026902B1 EA 026902 B1 EA026902 B1 EA 026902B1 EA 201270433 A EA201270433 A EA 201270433A EA 201270433 A EA201270433 A EA 201270433A EA 026902 B1 EA026902 B1 EA 026902B1
Authority
EA
Eurasian Patent Office
Prior art keywords
epratuzumab
treatment
weeks
cells
dose
Prior art date
Application number
EA201270433A
Other languages
English (en)
Russian (ru)
Other versions
EA201270433A1 (ru
Inventor
Анна-Мари Новотнэй-Барри
Режиналь Хульхофен
Джеральд Л. Паркер
Вайолет А. Хоскин
Original Assignee
Юсб Фарма, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Юсб Фарма, С.А. filed Critical Юсб Фарма, С.А.
Publication of EA201270433A1 publication Critical patent/EA201270433A1/ru
Publication of EA026902B1 publication Critical patent/EA026902B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201270433A 2009-09-18 2010-08-26 Способ лечения системной красной волчанки эпратузумабом EA026902B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24379709P 2009-09-18 2009-09-18
PCT/EP2010/005225 WO2011032633A1 (en) 2009-09-18 2010-08-26 Treatment of autoimmune and inflammatory diseases with epratuzumab

Publications (2)

Publication Number Publication Date
EA201270433A1 EA201270433A1 (ru) 2012-10-30
EA026902B1 true EA026902B1 (ru) 2017-05-31

Family

ID=43063209

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270433A EA026902B1 (ru) 2009-09-18 2010-08-26 Способ лечения системной красной волчанки эпратузумабом

Country Status (13)

Country Link
US (1) US20110070227A1 (https=)
EP (1) EP2478012B1 (https=)
JP (1) JP5816905B2 (https=)
KR (1) KR20120100914A (https=)
CN (1) CN102574920A (https=)
AU (1) AU2010294905B2 (https=)
BR (1) BR112012006035A2 (https=)
CA (1) CA2774244A1 (https=)
EA (1) EA026902B1 (https=)
ES (1) ES2608661T3 (https=)
IN (1) IN2012DN02196A (https=)
MX (1) MX341117B (https=)
WO (1) WO2011032633A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
RU2553225C2 (ru) 2008-05-23 2015-06-10 Сива Корпорейшн Способ облегчения регенерации
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
US9757458B2 (en) * 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
JP6392765B2 (ja) 2012-10-12 2018-09-19 エイディーシー・セラピューティクス・エス・アーＡｄｃ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｓａ ピロロベンゾジアゼピン−抗体結合体
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015052535A1 (en) 2013-10-11 2015-04-16 Spirogen Sàrl Pyrrolobenzodiazepine-antibody conjugates
EA035419B9 (ru) 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Триспецифичные связывающие молекулы и способы их применения
EP3194439B1 (en) * 2014-09-19 2022-01-19 Siwa Corporation Anti-age antibodies for treating inflammation and auto-immune disorders
US9993535B2 (en) 2014-12-18 2018-06-12 Siwa Corporation Method and composition for treating sarcopenia
US10358502B2 (en) 2014-12-18 2019-07-23 Siwa Corporation Product and method for treating sarcopenia
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
HUE058854T2 (hu) 2016-02-19 2022-09-28 Siwa Corp Módszer és készítmény a rák kezelésére, az áttétes rákos sejtek elpusztítására és a rák áttétképzõdésének megelõzésére a fejlett glikációs végtermékek (AGE) elleni antitest alkalmazásával
KR20180133452A (ko) 2016-04-15 2018-12-14 시와 코퍼레이션 신경퇴행성 질환을 치료하기 위한 항-노화 항체
JP2019518763A (ja) 2016-06-23 2019-07-04 シワ コーポレーション 様々な疾患及び障害の治療において使用するためのワクチン
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
PT3528787T (pt) 2016-10-21 2026-03-11 Amgen Inc Formulações farmacêuticas e métodos para produzir as mesmas
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
RS61795B1 (sr) 2017-02-08 2021-06-30 Adc Therapeutics Sa Konjugati pirolobenzodiazepin antitela
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
CA3059803A1 (en) 2017-04-13 2018-10-18 Siwa Corporation Humanized monoclonal advanced glycation end-product antibody
CN110582505B (zh) 2017-04-18 2021-04-02 免疫医疗有限公司 吡咯并苯并二氮杂*缀合物
WO2018193102A1 (en) 2017-04-20 2018-10-25 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
CA3064804A1 (en) 2017-06-14 2018-12-20 Adc Therapeutics Sa Dosage regimes for the administration of an anti-cd19 adc
KR102270107B1 (ko) 2017-08-18 2021-06-30 메디뮨 리미티드 피롤로벤조디아제핀 컨쥬게이트
US11518801B1 (en) 2017-12-22 2022-12-06 Siwa Corporation Methods and compositions for treating diabetes and diabetic complications
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
EP3867280A4 (en) * 2018-10-18 2022-11-09 Sinomab Bioscience Limited METHODS OF TREATMENT OF RHEUMATOID ARTHRITIS
CN113631560B (zh) 2019-03-15 2025-02-18 麦迪穆有限责任公司 氮杂环丁烷并苯并二氮杂䓬二聚体和用于治疗癌症的包含它们的缀合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) * 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5484892A (en) * 1993-05-21 1996-01-16 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that block ligand binding to the CD22 receptor in mature B cells
DE69534530T2 (de) * 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
DE60042785D1 (de) * 1999-06-09 2009-10-01 Immunomedics Inc Immuntherapie von autoimmunerkrankungen durch die verwendung von b-zell spezifischen antikörpern
BRPI0315295C1 (pt) * 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
EP1999148B8 (en) * 2006-03-06 2014-03-05 Medlmmune, LLC Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
CN101490087B (zh) * 2006-05-30 2013-11-06 健泰科生物技术公司 抗体和免疫偶联物及其用途
US8283162B2 (en) * 2009-03-10 2012-10-09 Abbott Laboratories Antibodies relating to PIVKAII and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANOLIK, J.H. ARINGER, M.: "New treatments for SLE: cell-depleting and anti-cytokine therapies", BAILLIERE'S BEST PRACTICE AND RESEARCH. CLINICAL REUMATOLOGY, BAILLIERE TINDALL, LONDON, GB, vol. 19, no. 5, 1 October 2005 (2005-10-01), GB, pages 859 - 878, XP005140891, ISSN: 1521-6942, DOI: 10.1016/j.berh.2005.05.006 *
DÖRNER T., ET AL: "Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus.", ARTHRITIS RESEARCH THERAPY, BIOMED CENTRAL LTD, GB, vol. 8, no. 3, 21 April 2006 (2006-04-21), GB, pages 1 - 11, XP002609526, ISSN: 1478-6362, DOI: 10.1186/ar1942 *
DÖRNER THOMAS, GOLDENBERG D M: "Targeting CD22 as a strategy for treating systemic autoimmune diseases.", THERAPEUTICS AND CLINICAL RISK MANAGEMENT, DOVE MEDICAL PRESS LTD.,, NZ, vol. 3, no. 5, 1 October 2007 (2007-10-01), NZ, pages 953 - 959, XP002609527, ISSN: 1176-6336 *
JUWEID M: "TECHNOLOGY EVALUATION: EPRATUZUMAB, IMMUNOMEDICS/AMGEN", CURRENT OPINION IN MOLECULAR THERAPEUTICS, CURRENT DRUGS, LONDON, GB, vol. 05, no. 02, 1 April 2003 (2003-04-01), London, GB, pages 192 - 198, XP008022448, ISSN: 1464-8431 *
LOONEY R JOHN, ANOLIK J, SANZ I: "A perspective on B-cell-targeting therapy for SLE.", MODERN RHEUMATOLOGY ; OFFICIAL JOURNAL OF THE JAPAN COLLEGE OF RHEUMATOLOGY, SPRINGER-VERLAG, TO, vol. 20, no. 1, 1 February 2010 (2010-02-01), To, pages 1 - 10, XP002609529, ISSN: 1439-7609, DOI: 10.1007/S10165-009-0213-X *

Also Published As

Publication number Publication date
AU2010294905B2 (en) 2016-09-22
US20110070227A1 (en) 2011-03-24
EA201270433A1 (ru) 2012-10-30
BR112012006035A2 (pt) 2019-09-24
EP2478012A1 (en) 2012-07-25
IN2012DN02196A (https=) 2015-08-21
AU2010294905A1 (en) 2012-04-05
CN102574920A (zh) 2012-07-11
KR20120100914A (ko) 2012-09-12
ES2608661T3 (es) 2017-04-12
CA2774244A1 (en) 2011-03-24
JP5816905B2 (ja) 2015-11-18
JP2013505205A (ja) 2013-02-14
MX341117B (es) 2016-08-09
EP2478012B1 (en) 2016-11-09
MX2012002907A (es) 2012-04-30
WO2011032633A1 (en) 2011-03-24

Similar Documents

Publication Publication Date Title
EA026902B1 (ru) Способ лечения системной красной волчанки эпратузумабом
TW202031287A (zh) 利用抗fcrn抗體治療葛瑞夫茲氏眼病之方法
JP2019503674A (ja) 抗ｌａｇ３抗体および抗原結合性フラグメント
TWI612059B (zh) 泛－ＥＬＲ<sup>＋</sup>ＣＸＣ趨化因子抗體
JP2000095800A (ja) エリトロポエチン受容体を活性化する抗体
JP4857396B1 (ja) 融合蛋白質
EA023406B1 (ru) Антитела к гепцидину и варианты их применения
TW202438530A (zh) 雙特異性抗體
KR20220007086A (ko) T1dm 및 췌도염의 치료에 사용하기 위한 항-cd40 항체
US20210000969A1 (en) Monoclonal antibody specifically binding to human plasmalemma vesicle-associated protein pv-1, preparation and use thereof
US20260116986A1 (en) Epo receptor agonists and antagonists
KR20210070303A (ko) 항-인간 cd45rc 항체 및 이의 용도
US20240109977A1 (en) Anti-cd38 antibodies and their uses
US20240400658A1 (en) Anti-periostin humanized monoclonal antibody, and preparation method therefor and use thereof
CN121311504A (zh) 用针对cd3和cd20的双特异性抗体治疗淋巴瘤的方法
CN118126181A (zh) 人和猴交叉种属抗ccr8膜蛋白抗体
CN119768431A (zh) Igf1r抗体
JP2024502670A (ja) Ｇａｒｐタンパク質抗体及びその適用
JP2023530187A (ja) 抗ａｎｇ－２抗体とその用途
US12084690B2 (en) Recombinant hARSA that crosses the blood brain barrier
CN115611980A (zh) 乙肝治疗用抗体
CN114591428A (zh) 抗Dsg1抗体及其应用
HK40099176A (zh) 抗cd38抗体及其用途
HK1172909A (en) Treatment of autoimmune and inflammatory diseases with epratuzumab
JPWO1999040118A1 (ja) ヒトｖｅｇｆ受容体ｋｄｒに対する抗体

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU